Development of new antimalarial drugs.
D000655:Amodiaquine / Q000627:therapeutic use; D000962:Antimalarials / Q000627:therapeutic use*; D002738:Chloroquine / Q000494:pharmacology / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D005493:Folic Acid Antagonists / Q000627:therapeutic use; D006801:Humans; D008288:Malaria / Q000188:drug therapy*; D000432:Methanol / Q000627:therapeutic use; D010616:Phenanthrenes / Q000627:therapeutic use; D010963:Plasmodium falciparum / Q000187:drug effects; D011319:Primaquine / Q000627:therapeutic use; D002727:Proguanil / Q000627:therapeutic use; D011739:Pyrimethamine / Q000627:therapeutic use; D011804:Quinolines / Q000627:therapeutic use; D012106:Research; D013411:Sulfadiazine / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D013450:Sulfones / Q000627:therapeutic use; D014481:United States
D000962:Antimalarials; D005493:Folic Acid Antagonists; D010616:Phenanthrenes; D011804:Quinolines; D013449:Sulfonamides; D013450:Sulfones; D013411:Sulfadiazine; D000655:Amodiaquine; D002738:Chloroquine; D011319:Primaquine; D002727:Proguanil; D000432:Methanol; D011739:Pyrimethamine